Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Found vs Kin Meds

By GLP-1 ScorecardUpdated

FoundFactor scores not reassessed.
Site position #7

Higher score

Kin MedsFactor scores not reassessed.
Site position #147

Lower score

Score comparison

Found has the higher recorded score — 83.5/100 to 69.1/100.

Found grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Found offers compounded, brand-name and oral GLP-1 routes, but their bills differ: compounded plans include medication and care, while branded medication and labs cost extra.

Before you choose

Before comparing the headline prices, the Found review and the Kin Meds review set out what each semaglutide figure in the table below covers, including whether the medication is a brand-name product billed by a pharmacy. Brand-name and compounded prices are different products, so set like against like before treating either one as cheaper.

If neither one fits, Found vs Klinic and Kin Meds vs MedLeanRx compare each of them with another graded program, and the list of alternatives to Found ranks the programs closest to Found on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueFound +4
78
74
Dose & formulationFound +1
94
93
Clinical oversightFound +31
86
55
Labs & monitoringFound +29
82
53
FulfillmentFound +12
84
72
Contract termsFound +15
70
55
Found · top barKin Meds · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricFoundKin Meds
WeighScore83.5/10069.1/100
GradeBC
Site position#7#147
Semaglutide$149 first, then $269 every 28 days on the one-term cash compounded plan (labs extra; confirm selected terms)Wegovy advertised from $149/mo; selected total unverified
Tirzepatide$199 first, then $339 every 28 days on the one-term cash compounded plan (labs extra; confirm selected terms)Zepbound advertised from $149/mo; selected total unverified
CoverageU.S. service with state, treatment and insurance restrictions; confirm your eligibilityCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
Found

Site position #7 · B

Factor scores not reassessed.

Strengths

  • Current compounded offers include medication, membership and care, with separate semaglutide and tirzepatide price tables
  • Branded injection and oral options are listed, subject to prescription, stock and patient-specific terms
  • Insurance-track clinical visits and cash-pay care are distinguished in the public billing documents
  • Terms name possible independent medical groups and describe check-ins and messaging

What to consider

  • Cash compounded renewal rates differ by molecule and recur every 28 days, not a calendar month
  • Longer-term advertised rates and upfront-payment wording do not settle the selected charge or supply
  • Labs cost extra; insurance-track cost-sharing can add to the bill and does not reimburse compounded-medication fees
  • Refund wording about three days and the first consultation conflicts; rejection of a preferred GLP-1 is not disqualification from all treatment
  • The assigned compounder, actual treating practice and individual license status remain unresolved
  • A brand or oral menu listing does not establish a specific available prescription, complete price or clinical equivalence
Kin Meds

Site position #147 · C

Factor scores not reassessed.

FDAWarning letter issued to Kin Meds in February 2026. See the FDA warning-letter database.

Strengths

  • Lists Wegovy and Zepbound on separate product pages
  • Describes subscription cancellation through the patient account before shipment

What to consider

  • The advertised starting price leaves the selected bill and insurance costs unverified
  • The policy treats charged orders as final after carrier handoff
  • Confirm service availability and dispensing pharmacy for your prescription
  • FDA issued Kin Meds a warning letter in February 2026; the letter is public in FDA's warning-letter database

Featured provider

Found

Factor scores not reassessed.

Found scores 83.5/100 (B). Found offers compounded, brand-name and oral GLP-1 routes, but their bills differ: compounded plans include medication and care, while branded medication and labs cost extra.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard